A5034370730- Inflammatory Bowel Disease
- Microscopic Colitis
- Gallbladder and Bile Duct Disorders
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Pediatric Hepatobiliary Diseases and Treatments
- Biosimilars and Bioanalytical Methods
- Biliary and Gastrointestinal Fistulas
- Esophageal and GI Pathology
- MicroRNA in disease regulation
- Health Systems, Economic Evaluations, Quality of Life
- Gastric Cancer Management and Outcomes
- Circular RNAs in diseases
- Pancreatic and Hepatic Oncology Research
- Cancer-related molecular mechanisms research
- Pregnancy and Medication Impact
- Clostridium difficile and Clostridium perfringens research
- Gastrointestinal disorders and treatments
- Gut microbiota and health
- Dermatological and COVID-19 studies
- IL-33, ST2, and ILC Pathways
- Esophageal Cancer Research and Treatment
- Bariatric Surgery and Outcomes
- Hidradenitis Suppurativa and Treatments
- Colorectal Cancer Surgical Treatments
Ospedale Maggiore
2025
ASST Fatebenefratelli Sacco
2018-2023
University of Milan
2017-2022
Institut Paoli-Calmettes
2020
Luigi Sacco Hospital
2020
Ospedale San Giuseppe
2017-2019
University of Trieste
2015-2016
Fondazione Italiana Fegato
2015
Ospedale di Cattinara
2015
Summary Background Vedolizumab registration trials were the first to include elderly patients with moderate‐to‐severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real‐life data have been reported in this population. Aims We investigated effectiveness and safety of vedolizumab matched cohorts nonelderly UC CD patients. Methods The Long‐term Italian Effectiveness (LIVE) study is a retrospective‐prospective including who started from April 2016 June 2017. Elderly (≥65 years)...
Objective: COVID-19 pandemic has seriously affected Italy. Radical changes occurred in the Italian NHS and thus GI departments, as only urgent endoscopies were guaranteed. The study aimed to report how demand for endoscopy changed during Italy evaluate appropriateness of referrals Endoscopy Unit.
Background Budesonide‐MMX has an established role in the management of relapsing mild‐to‐moderate ulcerative colitis. Data regarding effectiveness and tolerability real‐life clinical practice are limited. Aim The aim this study was to assess use budesonide‐MMX colitis, as well short‐term practice. Methods We conducted a retrospective adult patients with colitis treated at four tertiary inflammatory bowel disease centres Italy from June 2016 February 2018. Demographic features patients,...
Objectives Comparative trials among biological drugs for the treatment of ulcerative colitis (UC) provided conflicting results. After patent expire infliximab originator, adalimumab, biosimilar, golimumab and vedolizumab have been approved in Italy. We compared efficacy these four biologics UC according to concept continuous clinical remission (CCR). Methods In a retrospective, multicentre study, all patients treated with or between 2014 2019 were included. All each other 1-year CCR rate,...
Video 1Endoscopic management of recurrent cholangitis after EUS-guided choledochoduodenostomy.
Abstract Background Recently, comparative trials among biologics in ulcerative colitis (UC) provided conflicting results on their reciprocal superiority or equivalence. Therefore, patients naive to biologics, the first-choice biological drug is uncertain. Methods In a retrospective, real-life, multicentre inception cohort study involving 11 Italian IBD tertiary centres, all consecutive patients, treated with adalimumab (ADA), infliximab biosimilar (CTP-13), golimumab (GOL) vedolizumab (VDZ)...
Aims We wanted to analyze the performance of GI Genius CADx in a real life context, comparing its results with outcome histological examination.